JPS56103111A - Sustained release medicine containing dipyridamole and its manufacture - Google Patents

Sustained release medicine containing dipyridamole and its manufacture

Info

Publication number
JPS56103111A
JPS56103111A JP303881A JP303881A JPS56103111A JP S56103111 A JPS56103111 A JP S56103111A JP 303881 A JP303881 A JP 303881A JP 303881 A JP303881 A JP 303881A JP S56103111 A JPS56103111 A JP S56103111A
Authority
JP
Japan
Prior art keywords
manufacture
sustained release
medicine containing
release medicine
containing dipyridamole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP303881A
Other languages
English (en)
Japanese (ja)
Other versions
JPS6116368B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html
Inventor
Guruubaa Peetaa
Buritsukuru Rorufu
Bosuraa Geruharuto
Sutoritsukaa Heruberuto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Dr Karl Thomae GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Karl Thomae GmbH filed Critical Dr Karl Thomae GmbH
Publication of JPS56103111A publication Critical patent/JPS56103111A/ja
Publication of JPS6116368B2 publication Critical patent/JPS6116368B2/ja
Granted legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP303881A 1980-01-12 1981-01-12 Sustained release medicine containing dipyridamole and its manufacture Granted JPS56103111A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19803000979 DE3000979A1 (de) 1980-01-12 1980-01-12 Neue dipyridamol-retardformen und verfahren zu ihrer herstellung

Publications (2)

Publication Number Publication Date
JPS56103111A true JPS56103111A (en) 1981-08-18
JPS6116368B2 JPS6116368B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1986-04-30

Family

ID=6091926

Family Applications (1)

Application Number Title Priority Date Filing Date
JP303881A Granted JPS56103111A (en) 1980-01-12 1981-01-12 Sustained release medicine containing dipyridamole and its manufacture

Country Status (32)

Country Link
US (1) US4367217A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0032562B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS56103111A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR221983A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE6585T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU539618B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1148084A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CS (1) CS232713B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DD (1) DD156943A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE3000979A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK158539C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES8207428A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI78835C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB2067073B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR73102B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK62184A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU184366B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE50807B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL61887A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN155158B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KE (1) KE3402A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA19040A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY8500559A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO157369C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ195994A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
OA (1) OA06720A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH17063A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL129290B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT72330B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG28184G (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
YU (1) YU42549B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA811661B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5948415A (ja) * 1982-08-12 1984-03-19 フアイザ−・インコ−ポレ−テツド 長時間活性持続マトリツクス錠剤
JP2000159692A (ja) * 1998-09-25 2000-06-13 Sankyo Co Ltd HMG―CoAレダクタ―ゼ阻害薬含有製剤
JP2008534681A (ja) * 2006-02-09 2008-08-28 テバ ファーマシューティカル インダストリーズ リミティド ジピリダモール持続放出製剤及びそれを調製のための方法
JP2009504796A (ja) * 2005-08-22 2009-02-05 ノバルティス アクチエンゲゼルシャフト pH依存性薬剤化合物、pH調整剤および遅延剤を含む医薬組成物

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
EP0064485B1 (en) * 1981-04-27 1985-07-24 Aktiebolaget Hässle New pharmaceutical preparation
DE3124090A1 (de) * 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
DE3126703A1 (de) 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
IE54171B1 (en) * 1982-06-22 1989-07-05 Univ Glasgow Device for introducing nutrients and/or therapeutic materials into ruminant animals
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
DK58983D0 (da) * 1983-02-11 1983-02-11 Leo Pharm Prod Ltd Farmaceutisk praeparat
DE3306250A1 (de) * 1983-02-23 1984-08-23 Basf Ag, 6700 Ludwigshafen Sphaerische einkristalle fuer pharmazeutische zwecke
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
KR880002139B1 (ko) * 1983-04-08 1988-10-17 베링거 인겔하임 리미티드 경구 투여용 정제의 제조방법
JPS6051106A (ja) * 1983-08-31 1985-03-22 Yamanouchi Pharmaceut Co Ltd 塩酸アモスラロ−ル持続性製剤
IE56459B1 (en) * 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
GB8414221D0 (en) * 1984-06-04 1984-07-11 Sterwin Ag Unit dosage form
GB8414220D0 (en) * 1984-06-04 1984-07-11 Sterwin Ag Medicaments in unit dose form
US4867984A (en) * 1984-11-06 1989-09-19 Nagin K. Patel Drug in bead form and process for preparing same
DE3627423A1 (de) * 1986-08-13 1988-02-18 Thomae Gmbh Dr K Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
WO1988002629A1 (en) * 1986-10-16 1988-04-21 American Health Products Corporation 2',3'-didesoxyadenosine composition
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
IL84599A0 (en) * 1986-12-09 1988-04-29 Byk Gulden Lomberg Chem Fab Pharmaceutical composition containing urapidil and process for the preparation thereof
DE3812799A1 (de) * 1988-04-16 1989-10-26 Sanol Arznei Schwarz Gmbh Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung
GB8813032D0 (en) * 1988-06-02 1988-07-06 Boehringer Ingelheim Int Antiviral pharmaceutical composition
US5196203A (en) * 1989-01-06 1993-03-23 F. H. Faulding & Co. Limited Theophylline dosage form
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5084278A (en) * 1989-06-02 1992-01-28 Nortec Development Associates, Inc. Taste-masked pharmaceutical compositions
AT397345B (de) * 1990-04-04 1994-03-25 Chemiefaser Lenzing Ag Pharmazeutisches präparat mit verzögerter wirkstofffreisetzung auf basis von hemicellulosen
WO1992020326A1 (en) * 1991-05-20 1992-11-26 Marion Laboratories, Inc. Multi-layered controlled release formulation
ES2173096T3 (es) * 1992-08-05 2002-10-16 Faulding F H & Co Ltd Composicion farmaceutica peletizada.
US20060263428A1 (en) * 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6129930A (en) * 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US20060067999A1 (en) * 1996-03-25 2006-03-30 Wyeth Extended release formulation
WO2000018396A1 (fr) * 1998-09-25 2000-04-06 Sankyo Company, Limited PREPARATIONS A BASE D'INHIBITEUR DE HMG-CoA
US6475493B1 (en) 1999-09-02 2002-11-05 Norstrum Pharmaceuticals, Inc. Controlled release pellet formulation
JP2003510349A (ja) * 1999-10-07 2003-03-18 ノヴァ−ニューロン インコーポレーテッド 線条体機能に必要な遺伝子、その使用、およびそれを調節するための化合物
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
EP1276470B1 (en) 2000-04-20 2007-05-02 Novartis AG Taste masking coating composition
US7064130B2 (en) * 2001-04-20 2006-06-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
NZ532310A (en) * 2001-10-05 2007-02-23 Combinatorx Inc Combinations comprising a tetra-substituted pyrimidopyrimidine and a corticosteroid for the treatment of immunoinflammatory disorders
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
JP2006516593A (ja) * 2003-02-07 2006-07-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Mmp−9依存性疾患の治療及び予防のためのジピリダモール又はモピダモールの使用
DE10306179A1 (de) 2003-02-13 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe
BRPI0409796A (pt) 2003-04-24 2006-05-30 Boehringer Ingelheim Int uso de dipiridamol ou mopidamol para tratamento e prevenção de doenças tromboembolìticas e distúrbios provocados pela formação excessiva de trombina e/ou pela expressão elevada de receptores de trombina
DE10339862A1 (de) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
US20050112199A1 (en) * 2003-09-24 2005-05-26 Mahesh Padval Therapeutic regimens for administering drug combinations
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
WO2005113006A2 (en) * 2004-05-13 2005-12-01 Boehringer Ingelheim International Gmbh Use of dipyridamole for treatment of resistance to platelet inhibitors
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
WO2006096434A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2006100281A2 (en) 2005-03-22 2006-09-28 Losan Pharma Gmbh Solubilized ibuprofen
WO2006125042A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
CA2617546C (en) 2005-08-03 2014-07-15 Boehringer Ingelheim International Gmbh Use of flibanserin in the treatment of obesity
US20070087056A1 (en) * 2005-08-09 2007-04-19 Claudia Guthmann Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility
GB0517204D0 (en) * 2005-08-22 2005-09-28 Novartis Ag Organic compounds
CA2626134C (en) * 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
ES2550035T3 (es) * 2006-01-27 2015-11-04 Adare Pharmaceuticals, Inc. Sistemas de administración de fármacos que comprenden un agente de bloqueo selectivo de la serotonina 5-HT3 débilmente básico y ácidos orgánicos
JP5787301B2 (ja) 2006-01-27 2015-09-30 アデア ファーマシューティカルズ,インコーポレイテッド 弱塩基性薬および有機酸を含む薬物送達系
KR20090005371A (ko) * 2006-05-09 2009-01-13 베링거 인겔하임 인터내셔날 게엠베하 폐경후 성욕 장애의 치료를 위한 플리반세린의 용도
WO2007139753A2 (en) * 2006-05-22 2007-12-06 Combinatorx, Incorporated Methods and compositions for the treatment of diseases or conditions associated with increased c-reactive protein, interleukin-6, or interferon-gamma levels
ATE456369T1 (de) 2006-06-30 2010-02-15 Boehringer Ingelheim Int Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
JP2009543839A (ja) * 2006-07-14 2009-12-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 女性の性的障害を治療するためのフリバンセリンの使用
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
EA200900264A1 (ru) 2006-08-14 2009-08-28 Бёрингер Ингельхайм Интернациональ Гмбх Композиции флибансерина и способ их приготовления
JP5220746B2 (ja) * 2006-08-25 2013-06-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 制御放出システム及びその製造方法
EP1894561A1 (en) * 2006-08-30 2008-03-05 Dr. Reddy's Laboratories Ltd. Dipyridamole pharmaceutical compositions
JP2010522714A (ja) * 2007-03-28 2010-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規な医薬組成物
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
US20090075955A1 (en) * 2007-09-19 2009-03-19 Combinatorx, Inc. Therapeutic regimens for the treatment of immunoinflammatory disorders
KR20100121601A (ko) * 2007-12-17 2010-11-18 콤비네이토릭스, 인코포레이티드 면역염증성 질환의 치료를 위한 치료요법
JP5783725B2 (ja) 2007-12-28 2015-09-24 インパックス ラボラトリーズ、 インコーポレイテッドImpax Laboratories, Inc. レボドパの放出制御製剤及びその使用
US20090196935A1 (en) * 2008-02-01 2009-08-06 Ahmed Salah U Pharmaceutical Capsules Comprising Extended Release Dipyridamole Pellets
US8133506B2 (en) 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
WO2010036975A2 (en) * 2008-09-25 2010-04-01 Teva Pharmaceutical Industries Ltd. Dipyridamole and acetylsalicylic acid formulations and process for preparing same
NZ595691A (en) * 2009-04-09 2013-06-28 Alkermes Pharma Ireland Ltd Drug delivery composition
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
EP2361615A1 (en) 2010-02-19 2011-08-31 Alfred E. Tiefenbacher GmbH & Co. KG Dipyridamole prolonged-release tablet
US10098845B2 (en) 2013-10-07 2018-10-16 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
CN105640909B (zh) 2014-11-14 2019-09-20 正大天晴药业集团股份有限公司 一种含有达比加群酯的药用组合物
WO2022140448A1 (en) 2020-12-22 2022-06-30 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2853420A (en) * 1956-01-25 1958-09-23 Lowey Hans Ethyl cellulose coatings for shaped medicinal preparations
US2928770A (en) * 1958-11-28 1960-03-15 Frank M Bardani Sustained action pill
US3081233A (en) * 1960-08-08 1963-03-12 Upjohn Co Enteric-coated pilules
US3247066A (en) * 1962-09-12 1966-04-19 Parke Davis & Co Controlled release dosage form containing water-swellable beadlet
NL297631A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1963-06-03
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
DE2010416B2 (de) * 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
DE2031871C3 (de) * 1970-06-27 1974-06-27 Roehm Gmbh, 6100 Darmstadt Überzugsmasse für Arzneiformen
GB1468172A (en) * 1973-03-28 1977-03-23 Benzon As Alfred Oral drug preparations
US3954959A (en) * 1973-03-28 1976-05-04 A/S Alfred Benzon Oral drug preparations
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
GB1479655A (en) 1974-03-08 1977-07-13 Beecham Group Ltd Antibiotic preparations
FR2353285A1 (fr) * 1975-09-17 1977-12-30 Doms Laboratoires Medicament vasodilatateur coronarien perfectionne
GB1576376A (en) * 1977-03-30 1980-10-08 Benzon As Alfred Multiple-unit drug dose
LU77353A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1977-05-16 1979-01-19
DD146547A5 (de) 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
IE48715B1 (en) * 1978-12-22 1985-05-01 Elan Corp Plc New galencial forms for administration of medicaments by oral route,with programmed release and processes for preparing same

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5948415A (ja) * 1982-08-12 1984-03-19 フアイザ−・インコ−ポレ−テツド 長時間活性持続マトリツクス錠剤
JP2000159692A (ja) * 1998-09-25 2000-06-13 Sankyo Co Ltd HMG―CoAレダクタ―ゼ阻害薬含有製剤
JP2009504796A (ja) * 2005-08-22 2009-02-05 ノバルティス アクチエンゲゼルシャフト pH依存性薬剤化合物、pH調整剤および遅延剤を含む医薬組成物
JP2013136637A (ja) * 2005-08-22 2013-07-11 Novartis Ag pH依存性薬剤化合物、pH調整剤および遅延剤を含む医薬組成物
JP2008534681A (ja) * 2006-02-09 2008-08-28 テバ ファーマシューティカル インダストリーズ リミティド ジピリダモール持続放出製剤及びそれを調製のための方法

Also Published As

Publication number Publication date
ES498393A0 (es) 1982-09-16
MY8500559A (en) 1985-12-31
MA19040A1 (fr) 1981-10-01
DK9481A (da) 1981-07-13
GB2067073A (en) 1981-07-22
ES8207428A1 (es) 1982-09-16
FI78835B (fi) 1989-06-30
DD156943A5 (de) 1982-10-06
CS23281A2 (en) 1984-06-18
FI78835C (fi) 1989-10-10
PT72330A (de) 1981-02-01
ZA811661B (en) 1982-09-29
FI810058L (fi) 1981-07-13
ATE6585T1 (de) 1984-03-15
GB2067073B (en) 1984-02-15
AU539618B2 (en) 1984-10-11
YU3981A (en) 1983-09-30
EP0032562B1 (de) 1984-03-14
SG28184G (en) 1985-02-15
CS232713B2 (en) 1985-02-14
IN155158B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1985-01-05
IE50807B1 (en) 1986-07-23
NO157369B (no) 1987-11-30
IE810040L (en) 1981-07-12
AU6615681A (en) 1981-07-16
DE3067058D1 (en) 1984-04-19
PH17063A (en) 1984-05-24
YU42549B (en) 1988-10-31
JPS6116368B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1986-04-30
KE3402A (en) 1984-06-08
NO810061L (no) 1981-07-13
CA1148084A (en) 1983-06-14
NO157369C (no) 1988-03-16
NZ195994A (en) 1984-04-27
PL129290B1 (en) 1984-04-30
DE3000979A1 (de) 1981-07-23
HU184366B (en) 1984-08-28
PL229157A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1981-09-18
DK158539B (da) 1990-06-05
HK62184A (en) 1984-08-17
GR73102B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1984-02-02
EP0032562A1 (de) 1981-07-29
AR221983A1 (es) 1981-03-31
US4367217A (en) 1983-01-04
PT72330B (de) 1982-07-23
DK158539C (da) 1990-11-05
IL61887A (en) 1984-09-30
OA06720A (fr) 1982-06-30

Similar Documents

Publication Publication Date Title
JPS56103111A (en) Sustained release medicine containing dipyridamole and its manufacture
JPS5791921A (en) Medicine and manufacture
JPS5750913A (en) Nifedipin-containing solid medicine and manufacture
JPS5777616A (en) Medicinal composition and manufacture
ZA815123B (en) Aspirin tablet and preparation thereof
IL63880A0 (en) Medicament containing 2-amino-6-trifluoromethoxy-benzothiazole
JPS57118794A (en) Imunosome and preparation thereof
JPS57123101A (en) Insecticide and tickicide and their use
PH21847A (en) Phenalkoxyalkyl-and phenoxyalkyl-substituted oxiranecarboxylic acids,their use and medicaments containing them
JPS5718624A (en) Drug and manufacture
JPS56169690A (en) Xanthinederivative and manufacture
JPS56103110A (en) Sustained release medicinal composition
JPS5788172A (en) Pyroxicam and manufacture
GB2067900B (en) Medicinal tablets
MW1681A1 (en) 2-nitroimidazoles and preparation thereof
JPS57122087A (en) Benzodiazepine compound and use as drug
ZA817796B (en) Use of anticholenergic drugs
IL62848A0 (en) Carbapenams and carbapen-2-ems and their preparation
JPS5756429A (en) Nose medicine and manufacture
JPS56138154A (en) Desacetylthymosin-alpha-1 and manufacture
JPS57120526A (en) Medicine containing kallikrein and manufacture
JPS56154476A (en) 4-halogenated-oxetane-2-ones and manufacture
JPS57106613A (en) Pharmacetical medicine
IL59066A0 (en) Plaster products and their manufacture
JPS56104884A (en) Substituted benzopyranotriazoles* their manufacture and medicinal composition containing them